HRP20231467T1 - Spojevi - Google Patents
Spojevi Download PDFInfo
- Publication number
- HRP20231467T1 HRP20231467T1 HRP20231467TT HRP20231467T HRP20231467T1 HR P20231467 T1 HRP20231467 T1 HR P20231467T1 HR P20231467T T HRP20231467T T HR P20231467TT HR P20231467 T HRP20231467 T HR P20231467T HR P20231467 T1 HRP20231467 T1 HR P20231467T1
- Authority
- HR
- Croatia
- Prior art keywords
- substituted
- compound
- salt
- hydroxy
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 16
- 150000003839 salts Chemical class 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- -1 C(O)NH 2 Chemical group 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 201000000493 colon squamous cell carcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000012972 squamous cell carcinoma of colon Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Claims (14)
1. Spoj formule (I):
[image]
,
ili njegova farmaceutski prihvatljiva sol, naznačen time što:
R1, R2, R3 i R4 se neovisno bira između:
(i) H;
(ii) C1-3 alkila, koji može biti supstituiran s:
hidroksi,
C1-2 alkoksi,
NH2,
fenilom,
C5-6 heteroarilom,
C1-4 alkil-karbamoilom, ili
acilamido;
(iii) C1-3 alkoksi, koji može biti supstituiran s C3-6 cikloalkilom, ili s jednom ili više fluornih skupina;
(iv) C3-6 cikloalkil;
(v) halogena;
(vi) CORC, gdje se RC bira između NRN1RN2, gdje se RN1 i RN2 neovisno bira između H i metila;
(vii) cijano, NH2, ili NO2; i
(viii) fenila ili C5-6 heteroarila, koji može biti supstituiran s metilom, hidroksi ili metoksi;
Ar je fenil, koji može biti supstituiran s jednom ili više skupina koje se bira između:
(i) C1-4 alkila, koji može biti supstituiran s hidroksi, C1-2 alkoksi, NH2, C1-4 alkil-karbamoilom, ili s jednom ili više fluornih skupina;
(ii) C3-6 cikloalkila;
(iii) hidroksi; cijano; NRN3RN4, gdje se RN3 i RN4 neovisno bira između H i metila; ili acilamido;
(iv) halogena;
(v) C1-3 alkoksi, koji može biti supstituiran s hidroksi, C(O)NH2, C3-6 cikloalkilom, fenilom, C5-6 heteroarilom, ili s jednom ili više fluornih skupina;
(vi) fenoksi, koji može biti supstituiran s fluorom;
(vii) fenila ili C5-6 heteroarila; ili
(viii) SF5 ili SO2CH3;
i gdje najmanje jedan od R1, R2, R3 i R4 nije H.
2. Spoj, ili sol, u skladu s patentnim zahtjevom 1, naznačen time što je najmanje jedan od R1, R2, R3 i R4 C1-3 alkil, koji može biti supstituiran s:
hidroksi,
C1-2 alkoksi,
NH2,
fenilom,
C5-6 heteroarilom,
C1-4 alkil-karbamoilom, ili
acilamido.
3. Spoj, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što je najmanje jedan od R1, R2, R3 i R4 C1-3 alkoksi, koji može biti supstituiran s C3-6 cikloalkilom, ili jednom ili više fluornih skupina.
4. Spoj, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je najmanje jedan od R1, R2, R3 i R4:
(a) C3-6 cikloalkil;
(b) CORC, gdje se RC bira između NRN1RN2, gdje se RN1 i RN2 neovisno bira između H i metila;
(c) cijano, NH2 ili NO2; ili
(d) fenil ili C5-6 heteroaril, koji može biti supstituiran s metilom, hidroksi ili metoksi.
5. Spoj, ili sol, u skladu s patentnim zahtjevom 1, naznačen time što:
(a) R4 je metoksi, R2 je CH2OCH3 ili CH2OCH2CH3, a R1 i R3 su H;
(b) R4 je metoksi, R2 je fenil, koji može biti supstituiran s metilom ili metoksi, a R1 i R3 su H;
(c) R4 je metoksi, R2 je C5-6 heteroaril, koji može biti supstituiran s metilom;
(d) R4 je metoksi, a R1, R2 i R3 su H;
(e) R4 je klor, R2 je C1-3 alkil ili brom, a R1 i R3 su H; ili
(f) R3 je C1-3 alkil, a R1, R2 i R4 su H.
6. Spoj, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je Ar supstituiran s C1-4 alkilom, koji može biti supstituiran s hidroksi, C1-2 alkoksi, NH2, C1-4 alkil-karbamoilom, ili jednom ili više fluornih skupina.
7. Spoj, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je Ar supstituiran s C1-3 alkoksi, koji može biti supstituiran s hidroksi, C(O)NH2, C3-6 cikloalkilom, fenilom, C5-6 heteroarilom, ili jednom ili više fluornih skupina.
8. Spoj, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je Ar supstituiran s:
(a) C3-6 cikloalkilom;
(b) hidroksi;
(c) cijano;
(d) NRN3RN4, gdje se RN3 i RN4 neovisno bira između H i metila; ili acilamido;
(e) fenoksi, koji može biti supstituiran s fluorom;
(f) fenilom ili C5-6 heteroarilom; ili
(g) SF5 ili SO2CH3.
9. Spoj, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je Ar:
(a) 5-etil-2-metoksifenil;
(b) 5-CF3-2-metoksifenil; ili
(c) 2,6-dimetoksifenil.
10. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivo pomoćno sredstvo.
11. Spoj, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi u postupku terapije.
12. Spoj, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi u liječenju raka.
13. Spoj, ili sol, namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što se rak bira između leukemije, akutne limfocitne leukemije, akutne mijeloidne leukemije, kronične limfocitne leukemije, kronične mijeloidne leukemije, nehodgkinovske leukemije, Hodgkinove bolesti, raka prostate, raka pluća, melanoma, raka dojke, raka debelog crijeva i rektuma, raka debelog crijeva, karcinoma pločastih stanica i raka želuca.
14. Spoj, ili sol, namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što se spoj primijenjuje istodobno ili uzastopno u odnosu na radioterapiju i/ili kemoterapiju.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1810092.5A GB201810092D0 (en) | 2018-06-20 | 2018-06-20 | Compounds |
| EP19734722.2A EP3810602B1 (en) | 2018-06-20 | 2019-06-20 | Compounds |
| PCT/EP2019/066337 WO2019243491A1 (en) | 2018-06-20 | 2019-06-20 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231467T1 true HRP20231467T1 (hr) | 2024-03-01 |
Family
ID=63042663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231467TT HRP20231467T1 (hr) | 2018-06-20 | 2019-06-20 | Spojevi |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US20200039945A1 (hr) |
| EP (2) | EP3810602B1 (hr) |
| JP (1) | JP2021529738A (hr) |
| KR (1) | KR20210022655A (hr) |
| CN (1) | CN112334466A (hr) |
| AR (1) | AR114972A1 (hr) |
| AU (1) | AU2019289888A1 (hr) |
| BR (1) | BR112020025869A2 (hr) |
| CA (1) | CA3101238A1 (hr) |
| CL (1) | CL2020003219A1 (hr) |
| CO (1) | CO2020014586A2 (hr) |
| CR (1) | CR20210032A (hr) |
| CU (1) | CU20200096A7 (hr) |
| DK (1) | DK3810602T3 (hr) |
| DO (1) | DOP2020000249A (hr) |
| EA (1) | EA202092451A1 (hr) |
| EC (1) | ECSP20075270A (hr) |
| FI (1) | FI3810602T3 (hr) |
| GB (1) | GB201810092D0 (hr) |
| GE (1) | GEP20227403B (hr) |
| HR (1) | HRP20231467T1 (hr) |
| IL (1) | IL279554A (hr) |
| LT (1) | LT3810602T (hr) |
| MA (1) | MA52948B1 (hr) |
| MD (1) | MD3810602T2 (hr) |
| MX (1) | MX2020012723A (hr) |
| NI (1) | NI202000092A (hr) |
| PE (1) | PE20210181A1 (hr) |
| PH (1) | PH12020500673A1 (hr) |
| PL (1) | PL3810602T3 (hr) |
| PT (1) | PT3810602T (hr) |
| RS (1) | RS64932B1 (hr) |
| SG (1) | SG11202010450VA (hr) |
| SI (1) | SI3810602T1 (hr) |
| TW (1) | TWI826471B (hr) |
| UY (1) | UY38270A (hr) |
| WO (1) | WO2019243491A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3471271A1 (en) | 2017-10-16 | 2019-04-17 | Acoustical Beauty | Improved convolutions of digital signals using a bit requirement optimization of a target digital signal |
| CR20210627A (es) * | 2019-06-18 | 2022-02-08 | Pfizer | Derivados de benzisoxazol sulfonimada |
| AU2020295006B2 (en) * | 2019-06-19 | 2023-11-09 | Ctxt Pty Ltd | Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives |
| JP2022540434A (ja) * | 2019-07-12 | 2022-09-15 | キャノピー グロウス コーポレイション | カンナビノイド誘導体 |
| BR112023000687A2 (pt) | 2020-07-15 | 2023-02-07 | Pfizer | Métodos e combinações de inibidores de kat6 para o tratamento de câncer |
| AU2022278733A1 (en) * | 2021-05-21 | 2023-11-30 | Aurigene Oncology Limited | Fused isoxazolyl compounds as kat6a inhibitors |
| WO2023280182A1 (zh) * | 2021-07-05 | 2023-01-12 | 杭州英创医药科技有限公司 | 作为kat6抑制剂的化合物 |
| KR20240046530A (ko) | 2021-08-10 | 2024-04-09 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 설폰아미드 유도체, 이의 제조 방법 및 이의 의학적 용도 |
| TW202334163A (zh) * | 2021-11-16 | 2023-09-01 | 香港商英矽智能科技知識產權有限公司 | 離胺酸乙醯基轉移酶6a (kat6a)抑制劑及其用途 |
| WO2023114710A1 (en) * | 2021-12-13 | 2023-06-22 | Aurigene Oncology Limited | Fused benzoisoxazolyl compounds as kat6a inhibitors |
| US20230303580A1 (en) * | 2022-03-28 | 2023-09-28 | Isosterix, Inc. | Inhibitors of the myst family of lysine acetyl transferases |
| US20230416240A1 (en) * | 2022-06-16 | 2023-12-28 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
| WO2024023703A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| TR199801530T2 (xx) | 1996-02-13 | 1998-11-23 | Zeneca Limited | VEGF �nhibit�rleri olarak kinazolin t�revleri. |
| JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | ４―アニリノキナゾリン誘導体 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| ATE359515T1 (de) | 1997-02-12 | 2007-05-15 | Electrophoretics Ltd | Proteinmarker für lungenkrebs und deren verwendung |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CZ306810B6 (cs) | 1999-02-10 | 2017-07-19 | Astrazeneca Ab | Použití chinazolinového derivátu jako inhibitoru angiogeneze |
| UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
| CA2399358C (en) | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| WO2001092224A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| BR0112225A (pt) | 2000-07-07 | 2003-05-06 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto |
| DK2385938T3 (en) * | 2009-01-12 | 2015-04-27 | Pfizer Ltd | Sulfonamidderivater |
| RU2015143834A (ru) * | 2013-03-15 | 2017-04-24 | Дженентек, Инк. | Замещенные бензоксазолы и способы их применения |
| RU2702113C2 (ru) * | 2014-04-23 | 2019-10-04 | Мицубиси Танабе Фарма Корпорейшн | Новое бициклическое или трициклическое гетероциклическое соединение |
| GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| US20220267260A1 (en) * | 2016-11-29 | 2022-08-25 | Epizyme, Inc. | Compounds containing a sulfonic group as kat inhibitors |
| CR20210627A (es) * | 2019-06-18 | 2022-02-08 | Pfizer | Derivados de benzisoxazol sulfonimada |
-
2018
- 2018-06-20 GB GBGB1810092.5A patent/GB201810092D0/en not_active Ceased
-
2019
- 2019-06-20 GE GEAP201915535A patent/GEP20227403B/en unknown
- 2019-06-20 PT PT197347222T patent/PT3810602T/pt unknown
- 2019-06-20 WO PCT/EP2019/066337 patent/WO2019243491A1/en active Application Filing
- 2019-06-20 MD MDE20210392T patent/MD3810602T2/ro unknown
- 2019-06-20 CR CR20210032A patent/CR20210032A/es unknown
- 2019-06-20 CN CN201980041013.4A patent/CN112334466A/zh active Pending
- 2019-06-20 EP EP19734722.2A patent/EP3810602B1/en active Active
- 2019-06-20 PL PL19734722.2T patent/PL3810602T3/pl unknown
- 2019-06-20 BR BR112020025869-5A patent/BR112020025869A2/pt unknown
- 2019-06-20 DK DK19734722.2T patent/DK3810602T3/da active
- 2019-06-20 AU AU2019289888A patent/AU2019289888A1/en active Pending
- 2019-06-20 JP JP2020571368A patent/JP2021529738A/ja active Pending
- 2019-06-20 KR KR1020217001354A patent/KR20210022655A/ko unknown
- 2019-06-20 RS RS20231178A patent/RS64932B1/sr unknown
- 2019-06-20 MA MA52948A patent/MA52948B1/fr unknown
- 2019-06-20 PE PE2020001917A patent/PE20210181A1/es unknown
- 2019-06-20 UY UY0001038270A patent/UY38270A/es unknown
- 2019-06-20 SG SG11202010450VA patent/SG11202010450VA/en unknown
- 2019-06-20 MX MX2020012723A patent/MX2020012723A/es unknown
- 2019-06-20 US US16/446,868 patent/US20200039945A1/en not_active Abandoned
- 2019-06-20 FI FIEP19734722.2T patent/FI3810602T3/fi active
- 2019-06-20 TW TW108121417A patent/TWI826471B/zh active
- 2019-06-20 SI SI201930674T patent/SI3810602T1/sl unknown
- 2019-06-20 EA EA202092451A patent/EA202092451A1/ru unknown
- 2019-06-20 HR HRP20231467TT patent/HRP20231467T1/hr unknown
- 2019-06-20 CU CU2020000096A patent/CU20200096A7/es unknown
- 2019-06-20 EP EP23202715.1A patent/EP4335439A2/en active Pending
- 2019-06-20 LT LTEPPCT/EP2019/066337T patent/LT3810602T/lt unknown
- 2019-06-20 CA CA3101238A patent/CA3101238A1/en active Pending
- 2019-06-21 AR ARP190101711A patent/AR114972A1/es unknown
-
2020
- 2020-11-23 EC ECSENADI202075270A patent/ECSP20075270A/es unknown
- 2020-11-24 CO CONC2020/0014586A patent/CO2020014586A2/es unknown
- 2020-12-02 NI NI202000092A patent/NI202000092A/es unknown
- 2020-12-09 PH PH12020500673A patent/PH12020500673A1/en unknown
- 2020-12-11 CL CL2020003219A patent/CL2020003219A1/es unknown
- 2020-12-17 DO DO2020000249A patent/DOP2020000249A/es unknown
- 2020-12-17 IL IL279554A patent/IL279554A/en unknown
-
2021
- 2021-08-03 US US17/392,356 patent/US20220153710A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231467T1 (hr) | Spojevi | |
| WO2008041053A3 (en) | Inhibitors of vegf receptor and hgf receptor signaling | |
| CO6190620A2 (es) | Triazoles biciclicos como moduladores de la proteina cinasa | |
| HRP20191482T1 (hr) | 18f-označeni psma ciljani pet reagensi | |
| RS52862B (en) | IMIDASO [1,2-A] Pyridine Compounds as Tyrosine Kinase Receptor Inhibitors | |
| AR115885A1 (es) | Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno | |
| AR048377A1 (es) | Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos | |
| RU2019116512A (ru) | Ингибиторы magl | |
| AR121600A1 (es) | Compuestos de oxoisoindolina sustituidos | |
| IN2014MN02175A (hr) | ||
| JP2020500178A5 (hr) | ||
| AR117544A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| RU2019115059A (ru) | Модуляторы ror-гамма | |
| RS54337B1 (en) | RECEPTORA TRPM8 ANTAGONISTS | |
| RS54248B1 (en) | NEW UNITS AS LISTS OF HISTAMINE H3 RECEPTORS | |
| SE9904673D0 (sv) | Novel compounds | |
| AR046311A1 (es) | Derivados de 1,2,4 tiadiazoles. composiciones farmaceuticas. | |
| AR073008A1 (es) | Compuestos de 2- aminopirimidina como potentes inhibidores de hsp-90 | |
| TW200732305A (en) | Cancer chemotherapy | |
| JP2019522048A5 (hr) | ||
| NO20064882L (no) | Kjemisk prosess | |
| AR033758A1 (es) | Compuestos 4-(fenil-(piperidinil-4-il)amino)benzamida | |
| AR118244A1 (es) | Compuestos de pirazolil pirimidinilamina como inhibidores de cdk2 | |
| AR036231A1 (es) | Derivados de 4-diarilamino piperidina,procedimiento para su preparacion, empleo de estos derivados para la fabricacion de medicamentos, composicion farmaceutica y compuestos intermediarios | |
| AR027039A1 (es) | Compuestos novedosos |